Pentesting for Biotech: Simulating a Cyberattack on Your Genomic Data
1 min read
Summary
Biotech firms are tempting targets for cyberattacks due to the high value of the sensitive data they hold, including patient genomes and precise drug formulas.
They are also at risk of facing legal penalties, reputational damage and certification loss if they fail to sufficiently protect genomic data.
Nation states and competitors are also known to target biotecht firms to steal intellectual property and other sensitive data.
A specialized approach to penetration testing – or simulating cyberattacks – is required, and should include threat modelling and AI and ML security testing.
Steps involved in penetration testing include defining the scope and performing a realistic threat scenario analysis, followed by the simulated cyberattack itself.
The results should be reported in a way that highlights vulnerabilities and offers actionable remediation steps to strengthen security posture.
Proactive identification of security gaps through biotech-specific penetration testing can help firms in the sector stay ahead of threats.